2018
DOI: 10.1186/s12885-018-5053-7
|View full text |Cite
|
Sign up to set email alerts
|

Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node

Abstract: BackgroundThree randomized trials have concluded at non inferiority of omission of complementary axillary lymph node dissection (cALND) for patients with involved sentinel node (SN). However, we can outline strong limitations of these trials to validate this attitude with a high scientific level. We designed the SERC randomized trial (ClinicalTrials.gov, number NCT01717131) to compare outcomes in patients with SN involvement treated with ALND or no further axillary treatment. The aim of this study was to analy… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
24
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
5
1

Relationship

3
3

Authors

Journals

citations
Cited by 19 publications
(28 citation statements)
references
References 27 publications
0
24
0
Order By: Relevance
“…In OTOASOR trial 19 , with randomization between cALND versus axillary radiotherapy, patients with tumors up to 3cm diameter, cN0, unifocal or multifocal and breast-conserving treatment or mastectomy were eligible: 48.7% of patients had tumors more than 2cm (231/474) with 11 20 , POSNOC trial with only 1 or 2 SN macro-metastases and conservative treatment or mastectomy with cALND or radiotherapy versus no other axillary treatment 21 , SERC trial 10,11 and BOOG 2013-07 trial for mastectomy and 1 to 3 involved SN by micro or macro-metastases with only mastectomies 22 , SENOMAC trial for patients with 1 or 2 SN macrometastases including mastectomies 23 .…”
Section: Discussionmentioning
confidence: 99%
See 4 more Smart Citations
“…In OTOASOR trial 19 , with randomization between cALND versus axillary radiotherapy, patients with tumors up to 3cm diameter, cN0, unifocal or multifocal and breast-conserving treatment or mastectomy were eligible: 48.7% of patients had tumors more than 2cm (231/474) with 11 20 , POSNOC trial with only 1 or 2 SN macro-metastases and conservative treatment or mastectomy with cALND or radiotherapy versus no other axillary treatment 21 , SERC trial 10,11 and BOOG 2013-07 trial for mastectomy and 1 to 3 involved SN by micro or macro-metastases with only mastectomies 22 , SENOMAC trial for patients with 1 or 2 SN macrometastases including mastectomies 23 .…”
Section: Discussionmentioning
confidence: 99%
“…We excluded patients with axillary cN1 or T3-4. SLNB was performed using combined isotopic and colorimetric detection or isotopic detection alone with peri-tumoral and/or sub areolar injection 11 . Although the methods used for SN histological examination were not standardized in the protocol, all sites proceeded similarly: serial sections were performed every 200 microns and stained with standard HE.…”
Section: Methodsmentioning
confidence: 99%
See 3 more Smart Citations